Osimertinib in advanced EGFR-T790M mutation-positive non-small cell lung cancer patients treated within the Special Use Medication Program in Spain: OSIREX-Spanish Lung Cancer Group.

Mariano ProvencioJosefa TerrasaPilar GarridoRosario García CampeloFrancisco AparisiPilar DizDavid AguiarCarlos García-GironJulia HidalgoCarlos AguadoJorge García GonzálezEmilio EstebanLorenzo Gómez-AldavaríTeresa MoranOscar JuanLuís Enrique CharaJuan L MartiRafael López CastroAna Laura OrtegaElia Martínez MorenoJuan CovesAna M Sánchez PeñaJoaquim Bosch-BarreraAmparo Sánchez GastaldoNatalia Fernández NúñezEdel Del BarcoManuel CoboDolores IslaMargarita MajemFátima NavarroVirginia Calvo

Published in: BMC cancer (2021)

Clinical trial registration number: NCT03790397 .

Keyphrases

small cell lung cancer
clinical trial
epidermal growth factor receptor
advanced non small cell lung cancer
quality improvement
tyrosine kinase
phase ii
healthcare
double blind
open label
adverse drug
study protocol
phase iii
emergency department
placebo controlled